Dewi Vernerey

433 total citations · 1 hit paper
7 papers, 239 citations indexed

About

Dewi Vernerey is a scholar working on Oncology, Surgery and Physiology. According to data from OpenAlex, Dewi Vernerey has authored 7 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Surgery and 2 papers in Physiology. Recurrent topics in Dewi Vernerey's work include Colorectal Cancer Treatments and Studies (2 papers), Nutrition and Health in Aging (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Dewi Vernerey is often cited by papers focused on Colorectal Cancer Treatments and Studies (2 papers), Nutrition and Health in Aging (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Dewi Vernerey collaborates with scholars based in France and United States. Dewi Vernerey's co-authors include Magali Svrcek, Romain Cohen, Marie‐Line Garcia‐Larnicol, Jérémie H. Lefèvre, Christelle de la Fouchardière, Christophe Louvet, Julie Henriques, Astrid Lièvre, Marine Jary and Thierry André and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and Journal for ImmunoTherapy of Cancer.

In The Last Decade

Dewi Vernerey

5 papers receiving 237 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

2022 220 citations Thierry André, David Tougeron et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Dewi Vernerey

Since Specialization

Citations

This map shows the geographic impact of Dewi Vernerey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dewi Vernerey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dewi Vernerey more than expected).

Fields of papers citing papers by Dewi Vernerey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dewi Vernerey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dewi Vernerey. The network helps show where Dewi Vernerey may publish in the future.

Co-authorship network of co-authors of Dewi Vernerey

This figure shows the co-authorship network connecting the top 25 collaborators of Dewi Vernerey. A scholar is included among the top collaborators of Dewi Vernerey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dewi Vernerey. Dewi Vernerey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity 2025 ·Journal of Cachexia Sarcopenia and Muscle ·(unknown), F. Pigneur, Marc Hilmi, (unknown), (unknown), Dewi Vernerey, Alain Luciani, Pascal Hammel, Julie Henriques, (unknown), Anthony Turpin	2
2	Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES) 2025 ·Digestive and Liver Disease ·Jérémie H. Lefèvre, Olivier Dubreuil, Raphaël Colle, David Tougeron, Angélique Vienot, Aurélien Dupré, (unknown), Denis Smith, (unknown), Benoist Chibaudel, (unknown), Dewi Vernerey, (unknown)	0
3	Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Christophe Borg, Aurélia Meurisse, Julie Henriques, (unknown), Christelle de la Fouchardière, David Tougeron, Thibault Mazard, Benoist Chibaudel, Christophe Tournigand, Dewi Vernerey, F. Pigneur, Thierry André, Romain Cohen	1
4	Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study 2024 ·Clinical Colorectal Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), Dewi Vernerey, (unknown), Pascale Cervera, (unknown), (unknown), Thierry André	0
5	New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma 2024 ·Annals of Surgery ·(unknown), Julie Henriques, Ludivine Beaussire, Nasrin Sarafan‐Vasseur, António Sá Cunha, Jean‐Baptiste Bachet, Dewi Vernerey, Frédéric Di Fiore, Lilian Schwarz, (unknown)	6
6	Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study breakdown → 2022 ·Journal of Clinical Oncology ·Thierry André, David Tougeron, Guillaume Piessen, Christelle de la Fouchardière, Christophe Louvet, Antoine Adenis, Marine Jary, Christophe Tournigand, Thomas Aparicio, Jérôme Desrame, Astrid Lièvre, Marie‐Line Garcia‐Larnicol, T. Pudlarz, Romain Cohen, (unknown), Dewi Vernerey, Julie Henriques, Jérémie H. Lefèvre, Magali Svrcek	220
7	Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study 2021 ·Molecular Oncology ·Marine Jary, Wenwei Liu, Dongyao Yan, (unknown), (unknown), (unknown), Isabelle Brochériou, Anthony Turpin, Nina Radosevic‐Robin, Pierre Bourgoin, (unknown), Romain Cohen, Dewi Vernerey, Thierry André, Christophe Borg, Kandavel Shanmugam, Magali Svrcek	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact